Orexo Ab · OMXSTO:ORX
Orexo Ab — Nordic-American Life Science Conference 2019
19 slides from Orexo Ab's conference presentation, Dec 5, 2019
Slide 1: Nordic-American Life Science Conference, Dec. 5, 2019
A profitable specialty pharmaceutical company – with the aim of becoming a leader within treatment of addiction Nordic-American Life Science Conference, Dec. 5, 2019 Robert DeLuca, President Orexo US Inc. Nasdaq Stockholm: ORX US OTC Market: ORXOY (ADR)
Slide 2: Company Overview
Company Overview Orexo
Slide 3: Orexo is a Swedish specialty pharmaceutical company
Orexo is a Swedish specialty pharmaceutical company • Focuses on treatment of addiction in all phases, from prevention Corporate Headquarters (Uppsala, Sweden) to treatment Corporate functions and • Broad pipeline with multiple assets based on innovative Development drug delivery technologies and di
Slide 4: Products & Pipeline
Products & Pipeline Orexo
Slide 5: Pipeline of multiple potential assets
Pipeline of multiple potential assets The partnership with GAIA has extended Orexo´s technology platform to also include Digital Therapies Phase Approved/Launched Exploratory Preclinical Registration 1 2 3 US EU RoW Commercial products Opioid Dependence Zubsolv® Orexo US, Mundipharma Australia & NZ
Slide 6: OX124 and OX125 – the projects at a glance
OX124 and OX125 – the projects at a glance Unmet medical need OX124 and OX125 concept • 70,200 people died from a drug overdose in the US in • Unique and improved nasal formulations of 2017 naloxone (OX124) and nalmefene (OX125) to • Synthetic opioids, such as fentanyl, are now the specifically addr
Slide 7: Committed to find new solutions to improve treatment of addiction
Committed to find new solutions to improve treatment of addiction Orexo has recently closed two deals with GAIA AG, a worldleader within digital therapeutics (DTx) GAIA develops OXD01 OXD02 vorvida® scientifically proven DTx (opioid use disorder, OUD) (alcohol use disorder, AUD) • GAIA has demonstra
Slide 8: Key Market & Sales
Key Market & Sales Orexo
Slide 9: Orexo focuses on the number one health crisis in the US
Orexo focuses on the number one health crisis in the US 14 May, 2018 CBS News 9
Slide 10: US buprenorphine MAT population likely to double by 2023
US buprenorphine MAT population likely to double by 2023 2017 & 2023 US Treated Population US Growth Rates ~6 M Treatment-Eligible Population ~6% p.a. ~3M (50%) ~4 M Tx-Eligible ~2M ~7% p.a. (untreated) (50%) Treated Population ~1.2M (~3M) (20%) Treated ~1.1M (no Bup MAT) (27%) ~12% p.a. ~1.8M Patie
Slide 11: YTD Year-over-year market growth at 14 percent
YTD Year-over-year market growth at 14 percent New market highs in Public and Commercial NTRx in Q3 and Zubsolv grows 16 percent in open business Q3 YoY Growth Quarterly NTRx Market Zubsolv® Zubsolv® total open* 1 800 000 Cash Commercial Public 1 600 000 +19% -5% +17% 1 400 000 1 200 000 +11% +1% +1
Slide 12: In Q3 2019 Zubsolv sales grew in SEK by 10 percent despite declined volume
In Q3 2019 Zubsolv® sales grew in SEK by 10 percent despite declined volume due to formulary changes Zubsolv Tablet Volume (rolling 4 week average) Average weekly sales Q3 2019 Zubsolv volume declined 450 000 Humana allows Gx due to loss of exclusive contracts Maryland FFS excl Humana, Envision 400
Slide 13: Entry of generic film caused loss of exclusive contracts
The entry of generic film caused the loss of exclusive contracts, but recent market dynamic will offer opportunities WellCare removes Humana removes United removes NJ enacted law for exclusivity on Zubsolv® exclusivity on Zubsolv exclusivity on Zubsolv Medicaid to reimburse Zubsolv Ohio, Texas, Flor
Slide 14: Financials
aa 2 O Cc © = i Orexo
Slide 15: Continued strong performance in Q3 2019
Continued strong performance in Q3 2019 Group Net Revenues LTM1 Growth USD 87 m 12% 83.4% from Zubsolv® (Zubsolv 20%) Group EBITDA LTM1 Growth USD 24 m 110% US EBIT LTM1 Growth USD 33 m 101% Cash position Q3 2019 Net Cash position Q3 2019 USD 85 m USD 55 m 1 LTM, Last Twelve Months Note: USD based o
Slide 16: Orexo US Operating Margin (LTM) grew to 45.2%
Orexo US Operating Margin (LTM) grew to 45.2% Sales and gross profit Operating Profit LTM LTM LTM USD m MUSD % 80 40,0 50% 35,0 70 40% 30,0 60 25,0 30% 20,0 50 15,0 20% 10,0 10% 40 5,0 30 - 0% Q2 2019 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q3 2019 Q3
Slide 17: Outlook
= O O yp =) O Orexo
Slide 18: Strong value drivers for long-term growth
Strong value drivers for long-term growth Future 1. Growing key market 2. Strong financial position and profitability value 14 percent growth YTD in 2019 in a market addressing one of the largest health crises ever in America and a Fueled by the US commercial organization which is an important cash
Slide 19: Thank You Q&A
Thank You Q&A IR Contact: Lena Wange, IR & Communications Manager, ir@orexo.com. For more information please visit www.orexo.com. You can also follow Orexo at Twitter @orexoabpubl, LinkedIn and YouTube